Soligenix, Inc. (SNGX) - OTCQB
  • Life Sciences Report | Send Message 27 Apr

    " $SNGX will be pursuing opportunities for partnership on SGX942 trials"- Grant Zeng. Read more: http://ow.ly/4naQqe
    Reply
      • Life Sciences Report | Send Message 27 Apr

        Soligenix Fosters Potent Pipeline Of Orphan Disease Compounds In Areas Of Unmet Medical Need $SNGX http://seekingalpha.com/p/2wj8l
        Reply
          • Life Sciences Report | Send Message 20 Apr

            " $SNGX's current valuation doesn't reflect the potential upside"- Ross Silver. Read more: http://ow.ly/4mV6bC
            Reply
              • Life Sciences Report | Send Message 6 Apr

                " $SNGX's dusquetide shows preclinical efficacy against a broad spectrum of infectious bacteria"- J. Kolbert. More: http://ow.ly/10nlUc
                Reply
                  • Anthony Alfidi | Send Message 2 Feb

                    Soligenix And Rare Diseases $SNGX http://seekingalpha.com/p/2u7n4
                    Reply
                      • Anthony Alfidi | Send Message 2 Feb

                        $SNGX Soligenix survives with non-dilutive funding for disease treatments and biodefense. http://goo.gl/ghj3kE
                        Reply
                          • Life Sciences Report | Send Message 20 May 2015

                            Exceptional Management And Disruptive Products Top The Investment Checklist For Vista... $SNGX, $XON http://seekingalpha.com/p/2e5dm
                            Reply
                              • Grant Zeng, CFA | Send Message 18 Feb 2015

                                Soligenix's SGX943 And SGX101 May Be A Solution For Melioidosis Treatment $SNGX http://seekingalpha.com/a/1qqt4
                                Reply
                                  • PICOLOMINI | Send Message 14 Feb 2015

                                    $SNGX or $XON who will prevail with the Ricin vacine? Eough room for two?
                                    Reply
                                      • Tony Schwartz, PhD | Send Message 20 Oct 2014

                                        Soligenix: A Low Risk, High Return Biotech Stock $SNGX http://seekingalpha.com/a/1j7zn
                                        Reply
                                          Company Description
                                          We are a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. We maintain two active business segments: BioTherapeutics and Vaccines/BioDefense. Our BioTherapeutics business segment is developing a... More
                                          Sector: Healthcare
                                          Industry: Drug Manufacturers - Other
                                          Country: United States